Join to View Full Profile
31 Center Drive Bldg 31 Suite 3A44Bethesda, MD 20892
Phone+1 240-781-3398
Fax+1 240-541-4515
Dr. Takebe is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1994 - 1999
Sutter Health/California Pacific Medical CenterResidency, Internal Medicine, 1991 - 1994
OtherClass of 1988
Certifications & Licensure
CA State Medical License 1992 - Present
MD State Medical License 1999 - 2025
OK State Medical License 2024 - 2025
NY State Medical License 1994 - 1999
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Testing the Safety of CB-5339 in Patients With Cancer Start of enrollment: 2020 Jun 18
- Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel Start of enrollment: 2020 Aug 24
- A Phase 1 Trial of the p97 Inhibitor CB-5339 in Patients With Advanced Solid Tumors and Lymphomas
Publications & Presentations
PubMed
- Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma.Eudocia Q Lee, Brian M Alexander, Carlos G Romo, Jeffrey G Supko, Nathalie Y R Agar
Clinical Cancer Research. 2025-03-17 - A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors.Susan C Scott, Anna Farago, W Victoria Lai, Marianna Zahurak, Michelle A Rudek
Cancer Chemotherapy and Pharmacology. 2025-02-25 - Combinatorial screen of targeted agents with the PI3K inhibitors inavolisib, alpelisib, duvelisib, and copanlisib in multi-cell type tumor spheroids.Thomas S Dexheimer, Zahra Davoudi, Nathan P Coussens, Thomas Silvers, Joel Morris
SLAS Discovery. 2025-02-23
Lectures
- Safety, tolerability, and antitumor activity of once-daily Wee-1 inhibitor AZD1775.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
- Phase I trial of z-endoxifen with estrogen receptor imaging in adults with advanced hormone receptorâ€positive solid tumors including desmoid and gynecologic tumors.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Grant Support
- A Lead Academic Participating Site in Oklahoma for the Design and Conduct of NCTN Clinical TrialsUNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR2019–2026
- A Lead Academic Participating Site in Oklahoma for the Design and Conduct of NCTN Clinical TrialsUNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR2019–2026
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
